Abbott Predicts Humira Will Become $1 Bil. Product In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Adalimumab continues to eat away at Enbrel’s share of the self-injectable rheumatoid arthritis market, accounting for 27% of new prescriptions, up 2.5 points from December, Abbott says.